Tracking a shortage from primary sources rather than rumour — setting out what I have, and where I think it stops being reliable.
An honest uncertainty about tracking a shortage rather than a disguised assertion.
I do not know the answer and I have not been able to find one. What I have is the shape of the question, which may be worth more than my guess at the answer.
Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage. That permission is jurisdiction-specific and time-limited (usually for the duration of the shortage).
Caveat: everything above assumes the paperwork is what it says it is.
International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is prudent if you can.
That distinction has done more work for me than anything else in this category.
Narrowing post #6, because the general version has more than one answer.
Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the regulatory website for shortages gives you advance notice.
An honest declaration on tracking a shortage: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
The most useful contribution is a link to the current official notice rather than an account of one pharmacy.
The step people skip is the one I have spelled out.
Everything in post #10 holds. The case it does not cover is the one I have.
Where an alternative within the class is available, the comparison is a clinical one and the doses are not equivalent.
I would not lead a decision with this, but I would not ignore it either.
Building on post #12 rather than restating it.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
Planning around a known shortage window is easier than reacting to one, and the notices give advance warning more often than people expect.
Stockpiling in response to a shortage worsens it, which is true and is a poor argument to make to somebody who has run out.
If the premise is wrong, everything after it is decoration.
The published shortage register maintained by the national regulator is the authoritative source here, and it is updated far more often than any thread.
The claim is narrower than it sounds, and deliberately so.
Taking post #16 at face value and following it one step further.
Shortage-driven price movement is real and is a separate question from availability.
Adding it because I spent an afternoon working it out and nobody should have to twice.
Adding the measurement that post #16 says would settle it.
Switching presentation or strength during a shortage is a prescribing decision rather than a substitution anybody should improvise.
Post #18 describes the usual case. This is about the unusual one.
A shortage of one presentation is not a shortage of all of them, and the published notices are specific about which.
None of the above is medical advice and I am not qualified to give any.
Regional differences during a shortage are large, and a supply position in one country says nothing about another.
That holds under the stated conditions and I have stated them.
Post #19 answers the question as asked. The question underneath it is different.
Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.
Same conclusion as the reply above, reached differently, which is mildly reassuring.
Genuine question rather than a rhetorical one: has anyone here actually observed tracking a shortage, as opposed to read about it? The thread is long and I cannot tell.
Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are different decisions.
Take the reasoning and check the arithmetic; I do not always get it right.
The version of tracking a shortage that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
Worth separating two things that post #23 runs together.
Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the regulatory website for shortages gives you advance notice.
A shortage of one presentation is not a shortage of all of them, and the published notices are specific about which.
I had written a reply contradicting post #27 and deleted it. Here is what survived.
Both are useful and different. The notice tells you the national position; the account tells you what is happening on the ground.
Confirming post #27 from a second method, which matters more than confirming it from a second person.
Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage. That permission is jurisdiction-specific and time-limited (usually for the duration of the shortage).